Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

In conclusion, NGS-based MRD is widely applicable to AML patients, is highly predictive of relapse and survival, and may help refine transplantation and posttransplantation management in AML patients.

Source: Blood - October 18, 2018 Category: Hematology Authors: Thol, F., Gabdoulline, R., Liebich, A., Klement, P., Schiller, J., Kandziora, C., Hambach, L., Stadler, M., Koenecke, C., Flintrop, M., Pankratz, M., Wichmann, M., Neziri, B., Büttner, K., Heida, B., Klesse, S., Chaturvedi, A., Kloos, A., Go0 Tags: Transplantation, Myeloid Neoplasia, Clinical Trials and Observations Source Type: research